Clinical Trials

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03923270 2026-04-01

Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer

25 enrolled

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04499053 2026-03-16

Durvalumab and Tremelimumab in Combination With Chemotherapy in HIV-infected Patients With Non-small Cell Lung Cancer

Phase 2 Recruiting

18 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03075527 2026-01-08

A Phase 2 Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma

Phase 2 Terminated

19 enrolled 12 charts

Mesothelioma

NCT05380713 2025-12-29

......SMARTEST Trial......

30 enrolled

BreastDermatologicGastrointestinalThoracic

Mesothelioma, Malignant

NCT02639026 2025-11-25

Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers

Phase 1 Completed

53 enrolled

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms

NCT03581487 2025-11-05

Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer

Phase 1/2 Completed

40 enrolled

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03237377 2025-10-14

Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer

Phase 2 Terminated

9 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung

NCT05932199 2025-09-25

Neoadjuvant Durvalumab and Tremelimumab With and Without Chemotherapy for Mesothelioma

Phase 1/2 Recruiting

52 enrolled

GastrointestinalHead & NeckThoracic

Mesothelioma

NCT03212469 2025-05-08

ABIMMUNE

Phase 1/2 Completed

54 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Neoplasms, Lung Neoplasms

NCT04585490 2025-05-06

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Phase 3 Recruiting

48 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04287894 2024-11-06

Induction

Phase 1 Terminated

18 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03022500 2024-05-29

Pulmonary sarcomatoid_MEDI4736+Treme

32 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03963414 2023-08-28

A Study of Durvalumab Plus Tremelimumab With Chemotherapy in Untreated ES-SCLC

Phase 1 Terminated

1 enrolled

Small Cell Lung Carcinoma

NCT04625699 2023-06-06

Study of Durvalumab + Tremelimumab in NSCLC Patients After Adjuvant Treatment

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT03275597 2023-05-15

Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition

Phase 1 Terminated

17 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03994393 2023-04-21

ILLUMINATE

100 enrolled

EGFR Mutant Advanced Non Small Cell Lung Cancer

NCT03975114 2023-03-24

MILES-5

460 enrolled

DermatologicGenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung

NCT04107168 2023-02-16

Microbiome Immunotherapy Toxicity and Response Evaluation

Unknown

1,800 enrolled

Kidney Neoplasms, Lung Neoplasms, Melanoma

NCT03164772 2022-10-10

Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC

Phase 1/2 Completed

61 enrolled 18 charts

Carcinoma, Non-Small-Cell Lung

NCT02592551 2022-09-29

MEDI4736 Or MEDI4736 + Tremelimumab In Surgically Resectable Malignant Pleural Mesothelioma

24 enrolled 22 charts

Mesothelioma

NCT02701400 2021-06-22

Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer

18 enrolled 13 charts

Small Cell Lung Carcinoma

NCT03085849 2018-12-10

SGI-110 Plus Durvalumab/Tremelimumab in SCLC

Phase 1 Completed

2 enrolled

Small Cell Lung Carcinoma

NCT03130764 2017-12-06

Durvalumab and Tremelimumab for Adjuvant Therapy of Resected NSCLC

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT02040064 2016-06-09

GEFTREM

Phase 1 Completed

27 enrolled

Carcinoma, Non-Small-Cell Lung

NCT02588131 2015-10-27

A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)

40 enrolled

Mesothelioma, Malignant

NCT01655888 2012-08-02

The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma

29 enrolled

Mesothelioma, Malignant

NCT01649024 2012-07-25

A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma

29 enrolled